Stralem Co Inc Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Stralem Co Inc reduced its stake in Merck & Co. by 8.39% during the most recent quarter end. The investment management company now holds a total of 436,747 shares of Merck & Co. which is valued at $25,676,356 after selling 40,000 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.Merck & Co. makes up approximately 2.90% of Stralem Co Inc’s portfolio.

Other Hedge Funds, Including , Catawba Capital Management Va boosted its stake in MRK in the latest quarter, The investment management firm added 1,253 additional shares and now holds a total of 57,825 shares of Merck & Co. which is valued at $3,399,532. Merck & Co. makes up approx 0.80% of Catawba Capital Management Va’s portfolio.Leavell Investment Management boosted its stake in MRK in the latest quarter, The investment management firm added 2,415 additional shares and now holds a total of 77,270 shares of Merck & Co. which is valued at $4,542,703. Merck & Co. makes up approx 0.66% of Leavell Investment Management’s portfolio.Hengehold Capital Management boosted its stake in MRK in the latest quarter, The investment management firm added 17 additional shares and now holds a total of 29,403 shares of Merck & Co. which is valued at $1,728,602. Merck & Co. makes up approx 0.55% of Hengehold Capital Management’s portfolio.Davis R M Inc boosted its stake in MRK in the latest quarter, The investment management firm added 3,078 additional shares and now holds a total of 24,440 shares of Merck & Co. which is valued at $1,442,449. Merck & Co. makes up approx 0.07% of Davis R M Inc’s portfolio.Loring Wolcott Coolidge Fiduciary Advisors Llpma boosted its stake in MRK in the latest quarter, The investment management firm added 10,792 additional shares and now holds a total of 92,197 shares of Merck & Co. which is valued at $5,490,331. Merck & Co. makes up approx 0.12% of Loring Wolcott Coolidge Fiduciary Advisors Llpma’s portfolio.

Merck & Co. opened for trading at $59 and hit $59.119 on the upside on Wednesday, eventually ending the session at $58.79, with a gain of 0.22% or 0.13 points. The heightened volatility saw the trading volume jump to 64,76,048 shares. Company has a market cap of $162,732 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.